Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
about
Tafenoquine for preventing relapse in people with Plasmodium vivax malariaTafenoquine for Plasmodium vivax malaria infectionPrimaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquinePrimaquine for preventing relapses in people with Plasmodium vivax malariaTafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to datePrimaquine in vivax malaria: an update and review on management issuesA plant-derived morphinan as a novel lead compound active against malaria liver stagesUnderstanding the clinical spectrum of complicated Plasmodium vivax malaria: a systematic review on the contributions of the Brazilian literatureResistance to therapies for infection by Plasmodium vivaxIncreased bioavailability of primaquine using poly(ethylene oxide) matrix extended-release tablets administered to beagle dogs.Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.Antimalarial activities of new pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives.Antimalarial compounds in Phase II clinical development.Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects.Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta)Primaquine and relapses of Plasmodium vivax. Meta analysis of controlled clinical trials.Exposure-Response Analyses for Tafenoquine after Administration to Patients with Plasmodium vivax MalariaSingle-dose radical cure of Plasmodium vivax: a step closer.Atovaquone/proguanil for the prophylaxis and treatment of malaria.Antimalarial drug therapy: the role of parasite biology and drug resistance.Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinateTafenoquine: a promising new antimalarial agent.Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki.Management of relapsing Plasmodium vivax malariaPharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult SubjectsTafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infectionsTherapy of vector-borne protozoan infections in nonendemic settings.Emerging drugs for malaria.Evolution from double to triple-antimalarial drug combinations.Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers.Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania majorAntifungal drugs: predicting clinical efficacy with pharmacodynamics.Synthesis of [13C6]primaquine.Effects of supportive-expressive group therapy in breast cancer patients with affective disorders: a pilot study.A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria.Chloroquine-Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial.Occupational asthma from tafenoquine in the pharmaceutical industry: implications for QSAR.Recent updates in the discovery and development of novel antimalarial drug candidates
P2860
Q24186356-86FCF746-0D33-4958-A282-DD7783F9F25AQ24200381-63D26A1D-372D-468E-B6BD-3335536E0F7BQ24202900-F7C27812-A248-48A7-95B2-21FE1BEB457AQ24246197-9631565B-B737-4923-A8CF-EFA592AFFF88Q26741307-C8346279-3B1B-400E-994E-44C3B944FDA8Q27003856-F53C3AA2-5D66-414A-932F-F84D352D500AQ28469086-B042425E-D895-4CD7-B42A-C1D5F498DBA5Q33399080-4F534A20-989F-4121-89BD-64EC7AF1D761Q33481576-81D88319-79C5-477E-A760-2CBE6D3142ECQ33908425-EF30AF82-C919-41D9-B8D2-33206D804E64Q33962882-9345E782-DC24-4411-B36E-304017CF7BB5Q34228300-8C0DA0EE-9841-4EC6-96AB-8B190EBE017DQ34456807-469C0CBF-13BB-4766-8419-ABB088A4F11CQ34811224-A1265844-8BAA-4EFE-9001-795A6CACB6DCQ35181605-84CA5C47-81D8-4FB2-879F-2341E97170ABQ35555054-51DF9BDB-A9E9-40AB-97D7-BAE36B34FE3DQ36075824-6CEF4213-3769-4FC9-AD80-5CE8DB20B056Q36232674-A6FFBA5C-F31D-455B-8798-9CFDD7C5D256Q36322092-F19EDDB8-BE99-4661-BFCC-FD3F0CD075D3Q36652599-D42D23C3-68DA-40B8-A6C4-89FA7234A552Q36702987-EAA0B4F1-C24D-4FE6-ACD2-35B5CE60136AQ36802630-93673D7C-D559-4889-9222-F1D5FAA7EC6BQ37052790-441EEF5A-4CB0-4144-A368-B5B2E5935C0DQ37290599-BF4BCAEF-BC24-403E-8E69-9AEE3637B794Q37353434-9261123A-55CC-4CD6-8D08-AF59AA309D19Q37428670-84849A97-4791-4465-85D3-DDF24DEA92B2Q37485056-472B0772-8A2A-419B-A300-549ACB9DD83CQ37707806-3BD98574-D10D-40E1-81A8-5BBA1A1814FFQ37879203-3C1EFF50-B937-4590-BA56-66B2482F6CF8Q38027179-73A2802F-644C-4118-A7F2-C69EFCDAA86AQ38303998-C6779046-1D46-4E7D-AF45-D93D4A1398F9Q39413284-40F0195C-08D8-4757-9620-73B8731AC327Q41984797-B0719519-27A6-4512-9E39-95DD3BDC848FQ42723597-79EB13D5-F4EC-4408-95A4-AB1B2B9ED9BDQ45580143-BF11C912-FC3C-4CDD-9329-5F6B9C728A94Q47334799-BB1139BF-76B1-4BEA-8B73-545834B56478Q48015887-48CCE6E7-4653-43AC-8CDF-29DD10278C8FQ48016667-80D8DEA1-7116-4A39-8044-5FD1E2032BDEQ51660440-A558B55B-C990-4927-B205-978233C5FBECQ56403247-2E9DFB7B-1DC2-49DE-953B-7916EFFAEB1A
P2860
Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Randomized trial of 3-dose reg ...... smodium vivax malaria relapse.
@en
type
label
Randomized trial of 3-dose reg ...... smodium vivax malaria relapse.
@en
prefLabel
Randomized trial of 3-dose reg ...... smodium vivax malaria relapse.
@en
P2093
P2860
P50
P921
P356
P1476
Randomized trial of 3-dose reg ...... smodium vivax malaria relapse.
@en
P2093
D Gray Heppner
Douglas B Tang
Douglas S Walsh
Duangsuda Siriyanonda
Udomsak Silachamroon
Weerapong Phumratanaprapin
P2860
P304
P356
10.1086/424508
P407
P577
2004-09-24T00:00:00Z